Intrathecal chemotherapy with ACNU for meningeal gliomatosis
Author Information
Author(s): T.K. Yoshida, E. Beuls, K. Shimizu, A. Koulousakis, V. Sturm
Hypothesis
Is intrathecal administration of ACNU effective in treating meningeal gliomatosis in rats?
Conclusion
Intrathecal ACNU significantly prolongs survival in early stages of meningeal gliomatosis but is ineffective in late stages.
Supporting Evidence
- Intrathecal ACNU at dosages of 0.5 to 1.5 mg/kg significantly prolonged median survival time in early-stage meningeal gliomatosis.
- Intravenous ACNU at 15 mg/kg was more effective in late-stage meningeal gliomatosis compared to intrathecal administration.
- ACNU was ineffective in C6 glioma models in late stages but showed efficacy in 9L glioma models.
Takeaway
This study tested a medicine called ACNU in rats with a brain problem called meningeal gliomatosis. It worked well when given early but not later.
Methodology
Rats with meningeal gliomatosis were treated with ACNU either intrathecally or intravenously, and their survival times were compared.
Limitations
The study was conducted on rats, which may not fully represent human responses.
Participant Demographics
Male Wistar and Fischer 344 rats, approximately 100 gm each.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website